147 related articles for article (PubMed ID: 33997910)
1. Effect of morphological findings in computed tomography on the quantitative values in single-photon emission computed tomography for patients with antiresorptive agent-related osteonecrosis of the jaw: a cross-sectional study.
Kobayashi Y; Okui T; Tsujimoto M; Ikeda H; Satoh K; Kanamori D; Fujii N; Toyama H; Matsuo K
Ann Nucl Med; 2021 Jul; 35(7):853-860. PubMed ID: 33997910
[TBL] [Abstract][Full Text] [Related]
2. Histopathological findings affect quantitative values of single photon emission computed tomography in patients with antiresorptive agent-related osteonecrosis of the jaws.
Okui T; Kobayashi Y; Isomura M; Tsujimoto M; Satoh K; Toyama H
Fujita Med J; 2023 Aug; 9(3):186-193. PubMed ID: 37554942
[TBL] [Abstract][Full Text] [Related]
3. Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients.
Hata H; Kitao T; Sato J; Asaka T; Ohga N; Imamachi K; Hirata K; Shiga T; Yamazaki Y; Kitagawa Y
Sci Rep; 2020 Jul; 10(1):11385. PubMed ID: 32647190
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging.
Okui T; Kobayashi Y; Tsujimoto M; Satoh K; Toyama H; Matsuo K
Ann Nucl Med; 2020 Sep; 34(9):620-628. PubMed ID: 32557015
[TBL] [Abstract][Full Text] [Related]
5. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
6. Maximum and mean standardized uptake values of medication-related osteonecrosis of the jaw with bone SPECT/CT: comparison of mandibular pathologies, control and temporomandibular joints.
Tezuka Y; Ogura I
Dentomaxillofac Radiol; 2023 Sep; 52(6):20230119. PubMed ID: 37395742
[TBL] [Abstract][Full Text] [Related]
7. Comparison of single photon emission computed tomography-computed tomography, computed tomography and magnetic resonance imaging of medication-related osteonecrosis of jaw by new calculated parameters.
Minami Y; Ogura I
Q J Nucl Med Mol Imaging; 2024 Jun; 68(2):126-132. PubMed ID: 36287042
[TBL] [Abstract][Full Text] [Related]
8. Bone single-photon emission computed tomography-CT peak standardized uptake value for chronic osteomyelitis, osteoradionecrosis and medication-related osteonecrosis of the jaw.
Minami Y; Ogura I
J Med Imaging Radiat Oncol; 2021 Apr; 65(2):160-165. PubMed ID: 33180378
[TBL] [Abstract][Full Text] [Related]
9. Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value.
Ogawa R; Ogura I
Dentomaxillofac Radiol; 2021 Dec; 50(8):20200516. PubMed ID: 34019434
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
11. Comparison of maximum and mean standardized uptake values of jaw pathologies with bone SPECT/CT: an especial focus on medication-related osteonecrosis of the jaw.
Minami Y; Ogura I
Nucl Med Commun; 2022 Dec; 43(12):1188-1194. PubMed ID: 36345763
[TBL] [Abstract][Full Text] [Related]
12. Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw.
Assaf AT; Zrnc TA; Remus CC; Adam G; Zustin J; Heiland M; Friedrich RE; Derlin T
J Craniomaxillofac Surg; 2015 Oct; 43(8):1461-9. PubMed ID: 26232916
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
[TBL] [Abstract][Full Text] [Related]
14. Quantitative SPECT/CT imaging for medication-related osteonecrosis of the jaw: a preliminary study using volume-based parameters, comparison with chronic osteomyelitis.
Ogura I; Kobayashi E; Nakahara K; Igarashi K; Haga-Tsujimura M; Toshima H
Ann Nucl Med; 2019 Oct; 33(10):776-782. PubMed ID: 31342316
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
[TBL] [Abstract][Full Text] [Related]
17. Maximum standardized uptake value of normal structures in the head and neck with bone SPECT/CT.
Tezuka Y; Ogura I
J Med Imaging Radiat Oncol; 2022 Oct; 66(7):936-939. PubMed ID: 34989162
[TBL] [Abstract][Full Text] [Related]
18. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
Nashi M; Hirai T; Iwamoto T; Takenobu T
J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
[TBL] [Abstract][Full Text] [Related]
19. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
[TBL] [Abstract][Full Text] [Related]
20. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
